LB80380: a promising new drug for the treatment of chronic hepatitis B (Q58235869)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18808318%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

review article

1 reference

title

LB80380: a promising new drug for the treatment of chronic hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18808318%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18808318%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Ching-Lung Lai

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18808318%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Man-Fung Yuen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18808318%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

language of work or name

English

0 references

publication date

1 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18808318%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

14 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18808318%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18808318%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18808318%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

1581-1588

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18808318%20AND%20SRC:MED&resulttype=core&format=json

The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points.

14 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Perspectives for the treatment of hepatitis B virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Physiological concentrations of purines and pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

Prevention of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1581

10.1517/13543784.17.10.1581

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18808318%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference